AUTHOR=Yu Yang , Yu Min , Li Yanying , Zhou Xiaojuan , Tian Tian , Du Yijia , Tu Zegui , Huang Meijuan 

TITLE=Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review

JOURNAL=Frontiers in Oncology

VOLUME=Volume 12 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.945620

DOI=10.3389/fonc.2022.945620

ISSN=2234-943X

ABSTRACT=BRAF gene has become an oncogenic driver and a potential drug target in a wide variety of malignancies. BRAF fusion, a subtype of BRAF alteration, occurs at a very low frequency. Here, we report the first case of a heavily pre-treated advanced lung adenocarcinoma patient with de novo SND1-BRAF fusion showed partial response to trametinib. A review of the literature on targeting BRAF fusions is provided.